Antiviral treatment of cytomegalovirus infection: an update

Bibliography

• Schreiber A, Harter G, Schubert A, Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009;10:191-209
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-95
   PubMed Web of Science ®Google Scholar
• Hantz S, Garnier-Geoffroy F, Mazeron MC, Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010;65:2628-40
   PubMed Web of Science ®Google Scholar
• Myhre HA, Haug DD, Kristiansen KI, Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011;92:217-23
   PubMed Web of Science ®Google Scholar
• Van Der Beek MT, Berger SP, Vossen AC, Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010;89:320-6
   PubMed Web of Science ®Google Scholar
• Humar A, Limaye AP, Blumberg EA, Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010;90:1427-31
   PubMed Web of Science ®Google Scholar
• Couzi L, Helou S, Bachelet T, High incidence of anticytomegalovirus drug resistance among D+R− kidney transplant recipients receiving preemptive therapy. Am J Transplant 2011; published online; doi: 10.1111/j.1600-6143.2011.03766.x
   Google Scholar
• Kampmann SE, Schindele B, Apelt L, Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection. Med Microbiol Immunol 2011;200:109-13
   PubMedGoogle Scholar
• Schindele B, Apelt L, Hofmann J, Improved detection of mutated human cytomegalovirus UL97 by pyrosequencing. Antimicrob Agents Chemother 2010;54:5234-41
   PubMedGoogle Scholar
• Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J Virol 2010;84:7195-203
   PubMedGoogle Scholar
• Posthuma CC, Van Der Beek MT, Van Der Blij-De Brouwer CS, Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus. J Clin Virol 2011;51:25-30
   PubMedGoogle Scholar
• Iwasenko JM, Scott GM, Naing Z, Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients. Transpl Infect Dis 2011;13:145-53
   PubMedGoogle Scholar
• Atkinson C, Emery VC. Cytomegalovirus quantification: where to next in optimising patient management? J Clin Virol 2011;51:223-8
   PubMedGoogle Scholar
• Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011;24:605-11
   PubMed Web of Science ®Google Scholar
• Boutolleau D, Burrel S, Agut H. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. Antiviral Res 2011;91:32-5
   PubMed Web of Science ®Google Scholar
• Chevillotte M, von Einem J, Meier BM, A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res 2010;85:318-27
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase III, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011;11:284-92
   PubMed Web of Science ®Google Scholar
• Avery RK, Marty FM, Strasfeld L, Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010;12:489-96
   PubMed Web of Science ®Google Scholar
• Strasfeld L, Lee I, Tatarowicz W, Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010;202:104-8
   PubMed Web of Science ®Google Scholar
• Avery RK, Mossad SB, Poggio E, Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010;90:419-26
   PubMed Web of Science ®Google Scholar
• A multicenter, open-label study of CMX-001 treatment of serious diseases or conditions caused by dsDNA Viruses. Available from http://clinicaltrials.gov/ct2/show/NCT01143181 Last accessed 7 November 2011
   Google Scholar
• Chou S, Bowlin TL. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother 2011;55:382-4
   PubMedGoogle Scholar
• Chou S, Marousek G, Bowlin TL. Cyclopropavir Susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Antimicrob Agents Chemother 2011;56:197-201
   PubMedGoogle Scholar
• Wolf DG, Shimoni A, Resnick IB, Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011;90:183-6
   PubMed Web of Science ®Google Scholar
• Lau PK, Woods ML, Ratanjee SK, John GT. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011;52:279
   PubMed Web of Science ®Google Scholar
• Lischka P, Hewlett G, Wunberg T, In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010;54:1290-7
   PubMed Web of Science ®Google Scholar
• Goldner T, Hewlett G, Ettischer N, The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011;85:10884-93
   PubMed Web of Science ®Google Scholar
• Kaul DR, Stoelben S, Cober E, First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011;11:1079-84
   PubMed Web of Science ®Google Scholar
• Mui TS, Kapp M, Einsele H, Grigoleit GU. T-cell therapy for cytomegalovirus infection. Curr Opin Organ Transplant 2010; published online; doi: 10.1097/MOT.0b013e32834016b9
   PubMedGoogle Scholar
• Schmitt A, Tonn T, Busch DH, Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T-cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011;51:591-9
   PubMed Web of Science ®Google Scholar